Benzinga | Mar 9, 2021 09:16AM EST

Edesa Biotech Completes Enrollment In First Cohort Of Phase 2b Study Evaluating EB01 In Allergic Contact Dermatitis

TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the company's drug candidate EB01 as a monotherapy for chronic Allergic Contact Dermatitis (ACD), a potentially debilitating condition and occupational illness.